bta ann. is coming., page-8

This is the bit I like. Looks like demand is there.

"Clinical tests have confirmed that pandemic (H1N1) 2009 is sensitive to inhibitors of neuraminidase
such as Tamiflu and Relenza. Following the outbreak, GSK has contacted governments around the
world to ascertain demand for Relenza and has put in place a series of measures to raise production
levels. As a result, GSK now expects to increase its annual production capacity of Relenza to 190
million treatment courses by the end of 2009. This represents a threefold increase to GSK’s previous
maximum capacity of 60 million treatment courses."

cheers